Patents by Inventor Andrea VERGANI

Andrea VERGANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELL THERAPY FOR DIABETES
    Publication number: 20250057880
    Abstract: Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.
    Type: Application
    Filed: July 26, 2024
    Publication date: February 20, 2025
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Bote Bruinsma, Andrea Vergani, Felicia Pagliuca, George Harb, Jason Gaglia
  • Prevention and treatment of diabetic nephropathy
    Patent number: 12097172
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: September 24, 2024
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo Fiorina, Roberto Bassi, Andrea Vergani, Marcello Allegretti
  • CELL THERAPY FOR DIABETES
    Publication number: 20230332107
    Abstract: Disclosed herein are compositions, kits, and methods related to cell therapy for a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the methods provided herein relate to administration of non-native pancreatic cells to subject with a disease characterized by high blood glucose levels over a long period of time, such as diabetes. In some aspects, the disclosure provides pharmaceutical compositions including non-native cells.
    Type: Application
    Filed: January 31, 2023
    Publication date: October 19, 2023
    Inventors: Felicia PAGLIUCA, George HARB, Jason GAGLIA, Andrea VERGANI, Christopher THANOS
  • METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS)
    Publication number: 20230218775
    Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
    Type: Application
    Filed: August 24, 2022
    Publication date: July 13, 2023
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Paolo FIORINA, Andrea Vergani
  • Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)
    Patent number: 11452781
    Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: September 27, 2022
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Paolo Fiorina, Andrea Vergani
  • PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20220184009
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 16, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo FIORINA, Roberto BASSI, Andrea VERGANI, Marcello ALLEGRETTI
  • Prevention and treatment of diabetic nephropathy
    Patent number: 11291641
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 5, 2022
    Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo Fiorina, Roberto Bassi, Andrea Vergani, Marcello Allegretti
  • PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20190224148
    Abstract: Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DOMPE FARMACEUTICI S.P.A.
    Inventors: Paolo FIORINA, Roberto BASSI, Andrea VERGANI, Marcello ALLEGRETTI
  • METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS)
    Publication number: 20190184027
    Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
    Type: Application
    Filed: August 3, 2018
    Publication date: June 20, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Paolo FIORINA, Andrea VERGANI
  • Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis)
    Patent number: 10071167
    Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: September 11, 2018
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Paolo Fiorina, Andrea Vergani
  • METHOD OF PREVENTING AND TREATING TYPE 1 DIABETES, ALLOGRAFT REJECTION AND LUNG FIBROSIS (BY TARGETING THE ATP/P2X7R AXIS)
    Publication number: 20160067348
    Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
    Type: Application
    Filed: May 5, 2014
    Publication date: March 10, 2016
    Inventors: Paolo FIORINA, Andrea VERGANI